Valeant Pharmaceuticals International (VRX) 140.33 $VRX
After Yesterday's Decline of 2.50%, Valeant Pharmaceuticals International Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 4:01PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $138.80 to a high of $144.65. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $139.53 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 140.33 (-0.22)
Fresh Milestones For Dow, S&P 500 But Biotechs Hit
at Investor's Business Daily - Tue Dec 23, 1:48PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, but the Nasdaq lagged as biotech stocks sold off hard. The Dow added 0.6%, with about one-third of its components up 1% or more. The S&P 500 rose 0.4% and the Nasdaq...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), NOAH: 20.44 (-1.00), BIDU: 230.98 (-2.18), CALM: 42.45 (-1.73), ABG: 77.12 (+0.43), FLT: 149.17 (-0.93), REGN: 400.12 (+6.07)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive
at Investor's Business Daily - Mon Dec 22, 5:23PM CST
Investors turned a bit skittish on medical stocks Monday, as Gilead Sciences (GILD) plunged after Express Scripts (ESRX) announced it would support the hepatitis C drug from AbbVie (ABBV), rather than Gilead's Sovaldi. But two IBD Stock Spotlight...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)
Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 140.33 (-0.22), GILD: 91.29 (+1.84), SCMP: 13.75 (+0.44)
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)
Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)
The Early Retiree Portfolio For 2015
Early Retiree - at Seeking Alpha - Fri Dec 19, 5:17PM CST
CBI: 41.94 (-0.17), WAIR: 14.20 (unch), VRX: 140.33 (-0.22), DVA: 76.06 (+0.07), IBM: 161.82 (-0.42), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), GSK: 42.85 (+0.11), UG: 19.75 (-0.11)
Valeant Pharmaceuticals International Rises 2.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:53PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $142.56 to a high of $146.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $143.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 140.33 (-0.22)
Today's Momo Momentum Stock Is Valeant Pharmaceuticals International (VRX)
at The Street - Fri Dec 19, 1:19PM CST
Trade-Ideas LLC identified Valeant Pharmaceuticals International (VRX) as a momo momentum candidate
VRX: 140.33 (-0.22)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
An Exclusive Interview With Pershing Square's William (Bill) Ackman
Matt Stewart - at Seeking Alpha - Thu Dec 18, 8:30AM CST
ZTS: 43.84 (+0.87), AGN: 210.12 (+0.95), HLF: 37.98 (+0.20), VRX: 140.33 (-0.22), HHC: 133.21 (+0.49), PAH: 23.00 (+0.01), CP: 194.85 (-0.13), APD: 148.58 (unch), BKW: 35.50 (-1.16)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)
Insider Trading Alert - METR, VRX And EGBN Traded By Insiders
at The Street - Wed Dec 17, 10:41AM CST
Stocks with insider trader activity include METR, VRX and EGBN
VRX: 140.33 (-0.22), EGBN: 35.96 (+0.12), METR: 25.80 (+0.21)
Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:55PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized by its board of directors.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09)
Great Stocks: Valeant Pharmaceuticals Near Buy Point
at Investor's Business Daily - Tue Dec 16, 5:11PM CST
Drugmaker Valeant Pharmaceuticals is working on a new base as it prepares to issue its 2015 financial outlook. The base's cup-with-handle pattern shows a potential buy point at 147.49. But it's a risky, late-stage pattern, forming after the stock had...
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22)
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SPHS: 0.46 (+0.02), SCMP: 13.75 (+0.44)
After Yesterday's Decline of 2.50%, Valeant Pharmaceuticals International Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 4:01PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $138.80 to a high of $144.65. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $139.53 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 140.33 (-0.22)
Fresh Milestones For Dow, S&P 500 But Biotechs Hit
at Investor's Business Daily - Tue Dec 23, 1:48PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, but the Nasdaq lagged as biotech stocks sold off hard. The Dow added 0.6%, with about one-third of its components up 1% or more. The S&P 500 rose 0.4% and the Nasdaq...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), NOAH: 20.44 (-1.00), BIDU: 230.98 (-2.18), CALM: 42.45 (-1.73), ABG: 77.12 (+0.43), FLT: 149.17 (-0.93), REGN: 400.12 (+6.07)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive
at Investor's Business Daily - Mon Dec 22, 5:23PM CST
Investors turned a bit skittish on medical stocks Monday, as Gilead Sciences (GILD) plunged after Express Scripts (ESRX) announced it would support the hepatitis C drug from AbbVie (ABBV), rather than Gilead's Sovaldi. But two IBD Stock Spotlight...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)
Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 140.33 (-0.22), GILD: 91.29 (+1.84), SCMP: 13.75 (+0.44)
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)
Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)
The Early Retiree Portfolio For 2015
Early Retiree - at Seeking Alpha - Fri Dec 19, 5:17PM CST
CBI: 41.94 (-0.17), WAIR: 14.20 (unch), VRX: 140.33 (-0.22), DVA: 76.06 (+0.07), IBM: 161.82 (-0.42), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), GSK: 42.85 (+0.11), UG: 19.75 (-0.11)
Valeant Pharmaceuticals International Rises 2.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:53PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $142.56 to a high of $146.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $143.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 140.33 (-0.22)
Today's Momo Momentum Stock Is Valeant Pharmaceuticals International (VRX)
at The Street - Fri Dec 19, 1:19PM CST
Trade-Ideas LLC identified Valeant Pharmaceuticals International (VRX) as a momo momentum candidate
VRX: 140.33 (-0.22)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
An Exclusive Interview With Pershing Square's William (Bill) Ackman
Matt Stewart - at Seeking Alpha - Thu Dec 18, 8:30AM CST
ZTS: 43.84 (+0.87), AGN: 210.12 (+0.95), HLF: 37.98 (+0.20), VRX: 140.33 (-0.22), HHC: 133.21 (+0.49), PAH: 23.00 (+0.01), CP: 194.85 (-0.13), APD: 148.58 (unch), BKW: 35.50 (-1.16)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)
Insider Trading Alert - METR, VRX And EGBN Traded By Insiders
at The Street - Wed Dec 17, 10:41AM CST
Stocks with insider trader activity include METR, VRX and EGBN
VRX: 140.33 (-0.22), EGBN: 35.96 (+0.12), METR: 25.80 (+0.21)
Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:55PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized by its board of directors.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09)
Great Stocks: Valeant Pharmaceuticals Near Buy Point
at Investor's Business Daily - Tue Dec 16, 5:11PM CST
Drugmaker Valeant Pharmaceuticals is working on a new base as it prepares to issue its 2015 financial outlook. The base's cup-with-handle pattern shows a potential buy point at 147.49. But it's a risky, late-stage pattern, forming after the stock had...
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22)
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SPHS: 0.46 (+0.02), SCMP: 13.75 (+0.44)
